GlassScriptPhysician profile
Deborah D Desir
NPI 1831209865
$1,931.87
in general payments reported to CMS, 2019-2025
17 companies · $729 in 2025
The $729 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $881 · 2022: $185 · 2023: $137 · 2025: $729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $650 · Education: $137 · Food and Beverage: $78.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $650.00 |
| Education | $136.66 |
| Food and Beverage | $78.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $650.00 | 2025 | |
| Amgen INC. | $371.25 | 2019-2023 | |
| Janssen Biotech, INC. | $177.51 | 2019-2023 | Tremfya |
| Ucb, INC. | $125.76 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $97.84 | 2019 | |
| Janssen Scientific Affairs, LLC | $78.98 | 2025 | Tremfya |
| Genentech USA, INC. | $75.16 | 2019 | |
| Horizon Therapeutics Plc | $70.71 | 2019 | |
| Merck Sharp & Dohme LLC | $66.26 | 2019 | |
| Pfizer INC. | $51.72 | 2019 | |
| Glaxosmithkline, LLC. | $47.68 | 2019 | |
| Depuy Synthes Sales INC. | $39.62 | 2019 | |
| Fidia Pharma USA INC. | $24.12 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $16.77 | 2019 | |
| Alexion Pharmaceuticals, INC. | $14.36 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $12.42 | 2019 | |
| Abbvie INC. | $11.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Desir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.